CD8A and telomere syndrome: Therefore, given the fact that the dominant immune cells within subtype B were CD8+ T cells (the main killers of tumor cells, Philip and Schietinger, 2021) while the dominant immune cells within subtype C were M2 macrophages (the main tumor promoters, Najafi et al., 2019), we could explain why prognosis of subtype B STS was significantly better than that of subtype C STS.